Last reviewed · How we verify
Control vaccine with the adjuvant system.
This vaccine works by stimulating the body's immune system to produce a specific response against a target antigen.
This vaccine works by stimulating the body's immune system to produce a specific response against a target antigen. Used for Prevention of COVID-19.
At a glance
| Generic name | Control vaccine with the adjuvant system. |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
The adjuvant system in this vaccine helps to enhance the immune response by activating immune cells and increasing the production of antibodies. This leads to the development of immune memory, which can provide long-term protection against future infections.
Approved indications
- Prevention of COVID-19
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults (PHASE3)
- Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy (PHASE1)
- A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years (PHASE1)
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases (PHASE4)
- Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV (PHASE2)
- Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older (PHASE1, PHASE2)
- Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine (PHASE4)
- Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Control vaccine with the adjuvant system. CI brief — competitive landscape report
- Control vaccine with the adjuvant system. updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI